Prothena Begins Dosing in Study of Prasinezumab in Early Parkinson's Disease, Receives $60 Million Milestone Payment
05:31 AM EDT, 05/11/2021 (MT Newswires) -- Prothena (PRTA) said Monday it has begun dosing patients in its phase 2b PADOVA study of prasinezumab as a potential treatment to early Parkinson's disease.
The study, which will enroll about 575 patients, will determine the efficacy and safety of the drug candidate. The primary endpoint of the study is time to meaningful progression on motor signs of the disease, according to the statement.
The biopharmaceutical firm said it received a $60 million milestone payment from Roche as part of a collaborative deal with the company, adding to the previous payments amounting to $75 million.
Price: 23.39, Change: -1.23, Percent Change: -5.00